Overview

QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of QL1706 plus albumin-bound paclitaxel bevacizumab in 1L treatment of r/mTNBC
Phase:
PHASE2
Details
Lead Sponsor:
Fudan University
Treatments:
Bevacizumab
Taxes